Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belantamab |
Synonyms | |
Therapy Description |
Belantamab is a monoclonal antibody targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 34253590). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belantamab | GSK2857914|GSK-2857914|GSK 2857914 | TNFRSF17 Antibody 20 | Belantamab is a monoclonal antibody targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 34253590). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05714839 | Phase I | Belantamab Belantamab + belantamab mafodotin-blmf + Dexamethasone + Lenalidomide belantamab mafodotin-blmf | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) | Recruiting | TUR | POL | GBR | BRA | AUS | ARG | 3 |